



AQUA BIO TECHNOLOGY ASA

## AQUA BIO TECHNOLOGY ASA - RESULT OF SUBSEQUENT OFFERING

21.8.2023 13:36:38 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the "**Company**") on 8 August 2023 regarding a subsequent offering with gross proceeds of up to NOK 5,000,001 through issuance of up to 1,666,667 new shares at a subscription price of NOK 3.00 per share (the "**Subsequent Offering**"). In the Subsequent Offering, the shareholders of the Company as of 23 July 2023 (as registered in the VPS on 25 July 2023), except: (i) shareholders that subscribed for shares in the private placement placed on 23 July 2023, and (ii) shareholders who are resident in a jurisdiction where such offering would be unlawful, or would require any prospectus filing, registration or similar action (the "**Eligible Shareholders**"), received subscription rights giving preferential rights to subscribe for and be allocated new shares in the Subsequent Offering (the "**Offer Shares**"). In addition, certain groups of investors, as described in the stock exchange notice dated 8 August 2023 were given a secondary right to subscribe for Offer Shares not subscribed for by the Eligible Shareholders.

The application period in the Subsequent Offering ended on 18 August at 16.30 CEST. At the end of the application period, the Company had received applications corresponding to an oversubscription of approximately 270,000 Offer Shares. The new shares will be subscribed both through subscription rights and from Secondary Subscribers.

The Company's board of directors (the "**Board**") has now allocated shares in the Subsequent Offering, which implies that the Company shall issue 1,666,667 new shares related to the Subsequent Offering. The Board has allocated 1,442,978 Offer Shares to Eligible Shareholders and 270,644 Offer Shares to Secondary Subscribers. Allocation letters, regarding the number of shares allocated and the subscription amount to be paid, will be distributed to the subscribers shortly.

Completion of the Subsequent Offering is subject to approval of the share capital increase pertaining to the Subsequent Offering in the extraordinary general meeting of the Company to be held on 24 August 2023. Shareholders representing more than 2/3 of the shares in the Company has entered into voting undertakings where they have undertaken to vote in favour of such resolution.

For further information, please contact Håvard Lindstrøm, CEO, telephone +47 9413 2288.

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on Euronext Expand.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

### Disclosure regulation

This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.

### Contacts

- Håvard Lindstrøm, 004794132288, [hl@aquabiotech.no](mailto:hl@aquabiotech.no)

### About Aqua Bio Technology ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on Euronext Expand.

### Attachments

- [Download announcement as PDF.pdf](#)